Literature DB >> 2424971

Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells.

P M Sondel, J A Hank, P C Kohler, B P Chen, D Z Minkoff, J A Molenda.   

Abstract

Human and murine lymphocyte populations differentiate into lymphokine activated killer (LAK) cells after in vitro or in vivo exposure to interleukin 2 (IL 2). LAK cells mediate destruction of neoplastic tissue in vitro and have been reported to spare normal tissue. However, systemic toxicity is observed in mice and patients receiving IL 2 infusions. Some aspects of this toxicity are similar to that seen in graft-vs-host disease, suggesting that IL 2 may cause an immune-mediated destruction of normal tissues. We have evaluated this issue by examining the destructive potential of fresh human lymphocytes cultured in media containing highly purified recombinant human IL 2. In the absence of any exogenous antigen or allogeneic stimulating cells, strong proliferative responses were induced after 6 days of exposure to IL 2. Lymphocytes harvested from these 6-day cultures were highly cytotoxic to K562 and Daudi target cells. These IL 2-activated cells were also cytotoxic against autologous and allogeneic normal lymphocyte target cells. This autologous lymphocyte destruction was detected in media containing autologous serum and was directly dependent on the concentration of IL 2 added to the cultures. These studies demonstrate that populations of IL 2-activated lymphocytes, containing LAK activity, can mediate low-level but significant destruction of normal lymphocytes in vitro.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424971

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Simplified long term large scale production of highly active human LAK cells for therapy.

Authors:  P Wersäll; G Masucci; P Pihlstedt; H Wigzell; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

Review 2.  The interleukins in acquired disease.

Authors:  M Malkovský; P M Sondel; W Strober; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

3.  Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.

Authors:  S D Voss; J A Hank; C A Nobis; P Fisch; J A Sosman; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells.

Authors:  M Radrizzani; C Gambacorti-Passerini; G Parmiani; G Fossati
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 5.  Lymphokine activated killer cells.

Authors:  A Lindemann; F Herrmann; W Oster; R Mertelsmann
Journal:  Blut       Date:  1989-10

6.  Selective proliferation of natural killer cells among monocyte-depleted peripheral blood mononuclear cells as a result of stimulation with staphylococcal enterotoxin B.

Authors:  P Garcia-Peñarrubia; M P Lennon; F T Koster; R O Kelley; A D Bankhurst
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

7.  Human interleukin-2 activated cytotoxic cells kill autologous glioma cells in vitro.

Authors:  V Bosnes; H Hirschberg
Journal:  J Neurooncol       Date:  1988       Impact factor: 4.130

8.  Cytotoxic activity against maedi-visna virus-infected macrophages.

Authors:  W C Lee; I McConnell; B A Blacklaws
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Responses of killer cells in head and neck cancer patients.

Authors:  S Fujieda; H Saito; T Hoshino
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

10.  Generation of lymphokine-activated killer cells does not require DNA synthesis.

Authors:  M Malkovský; M Jíra; J Madar; V Malkovska; B Loveland; G L Asherson
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.